Document text
Principal Investigator: PETER Thornton FOX
Organization: UNIVERSITY OF TEXAS HLTH SCIENCE CENTER
Fiscal Year: 2024
Award: $929,085
Funding agency: National Institute on Aging
The ISAVRAD U19 proposes a five-site, two-arm (patients and controls), longitudinal (3 assessments/subject)
study enrolling 4,300 individuals. All 5 enrollment sites are experienced in recruiting genetically homogenous
cohorts. Pilot data of various types are provided in the respective projects and cores. Participants will be men
and women (~50:50 ratio) who are > 60 years of age and either have a history of polymerase chain reaction
(PCR) test positive COVID-19 infection (75% of sample) or have no history of COVID-19 (25% of sample).
Evaluations will be performed upon enrollment, 18 months, and 36 months. Evaluations will comprise a
standardized data acquisition battery including assessment of clinical status and serum sampling for fluid-based
biomarkers and genetics. Neuroimaging will be conducted at enrollment and at 18 months. Data acquisition,
preprocessing, archiving and sharing – both within the U19 and with the scientific community at large – will be
overseen by the Administrative, Clinical, Neuroimaging, and Data Management & Statistics Cores of the U19.
The Neuroimaging Core will manage neuroimaging acquisition (2 assessments/subject), quality control,
harmonization, data archiving and data sharing at all five study sites. Image acquisition, quality control and
harmonization strategies will emulate those of ADNI3 and Mark VCID supplemented by team expertise. Minimal
data preprocessing will use pipelined approaches both volumetric and surface-based. Surface-based analyses
will emulate Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) protocols, with the
expectation that other large studies of the post-acute sequelae of COVID-19 (PASC) will emerge and that
ENIGMA community will embrace the challenge of ongoing data exploration both meta-analytic and mega-
analytic.
Aim 1: Image Acquisition, Harmonization and Quality Control. Structural MRI and functional MRI images will be
acquired at all five study sites. Structural MRI acquisitions will emulate those of ADNI3, UKBioBank, Lifespan
HCP, MarkVCID and GOBS. Functional MRI acquisitions will emulate the latest GOBS. The Neuroimaging Core
will coordinate acquisition across sites, including harmonization and quality control.
Aim 2: Image Preprocessing and Pipeline analytics. The Neuroimaging Core will perform post-acquisition quality
control, image preprocessing (artifact removal, motion correction, etc.), and run widely used volumetric and
surface-based pipeline analyses. Blood-oxygen-level-dependent (BOLD)-based indices of neuronal dysfunction
will be cross validated with glucose metabolism and blood flow.
Aim 3: Image Archiving, Access Control, and Sharing. Anonymized raw and processed volumetric and surfaced-
based images and image-derived data (region of interest [ROI] values) and visual-inspection scores will be
archived in the XNAT system. Spreadsheet-compatible data will be provided to the Data Management and
Statistics Core.
Terms: <65 and older><65 or older><65 years of age and older><65 years of age or more><65 years of age or older><65+ years><65+ years old><> 65 years><AD dementia><AD related dementia><ADRD><APOE e4><APOE-ε4><APOEε4><Abscission><Active Follow-up><Age Years><Aged 65 and Over><Alzheimer Type Dementia><Alzheimer disease dementia><Alzheimer sclerosis><Alzheimer syndrome><Alzheimer's><Alzheimer's Disease><Alzheimer's and related dementias><Alzheimer's disease and related dementia><Alzheimer's disease and related disorders><Alzheimer's disease or a related dementia><Alzheimer's disease or a related disorder><Alzheimer's disease or related dementia><Alzheimer's disease related dementia><Alzheimers Dementia><Amentia><Archives><Artifacts><Biological Markers><Blood Serum><Blood flow><Brain><Brain Nervous System><COVID anosmia><COVID associated anosmia><COVID related anosmia><COVID smell loss><COVID survivors><COVID test><COVID tests><COVID-19><COVID-19 anosmia><COVID-19 associated anosmia><COVID-19 associated smell loss><COVID-19 induced anosmia><COVID-19 infection><COVID-19 infection survivors><COVID-19 olfactory dysfunction><COVID-19 positive><COVID-19 positivity><COVID-19 related anosmia><COVID-19 related olfactory dysfunction><COVID-19 smell loss><COVID-19 survivors><COVID-19 test><COVID-19 tests><COVID-19 virus infection><COVID-19-mediated anosmia><COVID-related smell loss><COVID19 infection><COVID19 test><COVID19 tests><CV-19><Clinical><Cognitive Disturbance><Cognitive Impairment><Cognitive decline><Cognitive function abnormal><Communities><Coronavirus Infectious Disease 2019><Data><Data Analyses><Data Analysis><Dementia><Disease><Disorder><Disturbance in cognition><Electronic Health Record><Encephalon><Enrollment><Evaluation><Excision><Extirpation><Functional MRI><Functional Magnetic Resonance Imaging><Genetic><Genetic Diversity><Genetic Variation><History><Image><Image data archive><Impaired cognition><Incidence><Individual><Infection><Liquid substance><MR Imaging><MR Tomography><MRI><MRIs><Magnetic Resonance Imaging><Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance><Meta-Analysis><Metabolic syndrome><Morphologic artifacts><Motion><NMR Imaging><NMR Tomography><Neuronal Dysfunction><Nuclear Magnetic Resonance Imaging><PASC><Participant><Pathway interactions><Patients><Phase><Polymerase Chain Reaction><Population><Post Acute Sequelae of COVID19><Post Acute Sequelae of SARS-CoV-2><Post Acute Sequelae of SARS-CoV2><Post Acute Sequelae of severe acute respiratory syndrome coronavirus 2><Post-Acute Sequelae of SARS-CoV-2 Infection><Primary Senile Degenerative Dementia><Process><Prospective, cohort study><Protocol><Protocols documentation><Quality Control><Recording of previous events><Removal><Research><Risk><Risk Factors><Running><SARS-CoV-2 induced anosmia><SARS-CoV-2 infection><SARS-CoV-2 mediated anosmia><SARS-CoV-2 positive><SARS-CoV-2 positivity><SARS-CoV-2 survivors><SARS-CoV-2 test><SARS-CoV-2 tests><SARS-CoV2 infection><Sampling><Serum><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 positive><Severe acute respiratory syndrome coronavirus 2 positivity><Severities><Site><Smoking><South Texas><Structure><Surface><Surgical Removal><Survivors><System><Testing><Visual><Woman><Zeugmatography><above age 65><active followup><adverse sequelae of COVID><adverse sequelae of COVID-19><adverse sequelae of coronavirus disease><adverse sequelae of coronavirus disease 2019><after age 65><age 65 and greater><age 65 and older><age 65 or older><age > 65><age of 65 years onward><aged 65 and greater><aged 65+><aged ≥65><analysis pipeline><anosmia associated with COVID-19><anosmia in COVID-19><anosmia with COVID-19><apo E-4><apo E4><apo epsilon4><apoE epsilon 4><apoE-4><apoE4><apolipoprotein E epsilon 4><apolipoprotein E-4><apolipoprotein E4><archive data><archiving data><arm><bio-markers><biobank><biologic marker><biomarker><biorepository><blood oxygen level dependent><blood oxygenation level dependent><chronic COVID-19 sequelae><co-morbid><co-morbidity><cognitive dysfunction><cognitive loss><cohort><comorbidity><coronavirus disease 2019><coronavirus disease 2019 infection><coronavirus disease 2019 positive><coronavirus disease 2019 positivity><coronavirus disease 2019 test><coronavirus disease 2019 tests><coronavirus disease test><coronavirus disease tests><coronavirus disease-19><coronavirus infectious disease-19><coronavirus test><coronavirus tests><data acquisition><data acquisitions><data archive><data archives><data exploration><data interpretation><data management><data sharing><data standardization><data standards><dementia risk><electronic health care record><electronic health medical record><electronic health plan record><electronic health registry><electronic medical health record><enroll><expectation><experience><fMRI><fluid><follow up><follow-up><followed up><followup><glucose metabolism><histories><human old age (65+)><image archival system><image archive><image library><image repository><imaging><imaging repository><indexing><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><interest><life span><lifespan><liquid><long haul sequelae of COVID-19><long haul sequelae of coronavirus disease 2019><long-term sequelae of COVID-19><long-term sequelae of SARS-CoV-2><long-term sequelae of coronavirus disease 2019><long-term sequelae of severe acute respiratory syndrome coronavirus 2><medial temporal area><medial temporal lobe><men><mesial temporal area><mesial temporal lobe><neural dysfunction><neural imaging><neuro-imaging><neuroimaging><neurological imaging><old age><olfactory dysfunction following COVID-19><olfactory dysfunction following SARS-CoV-2><olfactory dysfunction in COVID-19><olfactory dysfunction in SARS-CoV-2><over 65 years><pandemic><pandemic disease><pathway><picture archive><post COVID-19 sequelae><post acute sequelae following COVID-19><post-acute sequelae following SARS-CoV-2 infection><post-acute sequelae of COVID-19><post-acute sequelae of acute COVID infection><post-acute sequelae of coronavirus disease 2019><primary degenerative dementia><recruit><resection><risk factor for dementia><risk for dementia><senile dementia of the Alzheimer type><severe acute respiratory syndrome coronavirus 2 test><severe acute respiratory syndrome coronavirus 2 tests><smell loss associated with COVID-19><statistics><survive COVID-19><survive SARS-CoV-2><test for COVID><≥65 years>